In the last three months, 11 analysts have published ratings on AbbVie ABBV, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...
This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...
Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
For years, AbbVie's (ABBV) blockbuster rheumatoid-arthritis treatment, Humira, which launched in 2002, was the world's best-selling drug. Cigna said in August that it would remove Humira from some ...
AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and ...
(Reuters) - U.S. drugmaker AbbVie said on Monday it would acquire Aliada Therapeutics for $1.4 billion in cash, gaining access to the therapy developer's Alzheimer's disease drug candidate.
AbbVie is strengthening its neurology portfolio with a $1.4 billion acquisition of Aliada Therapeutics. The North Chicago-based drugmaker said in a statement this morning that Aliada has a blood ...
On CNBC's “Mad Money Lightning Round,” Jim Cramer said AbbVie Inc. ABBV is doing “very, very well.” However, he added that Abbott Laboratories ABT remains his favorite in the group right now.
AbbVie has made a big move in the Alzheimer’s space just a few months after it dropped its own internal candidate over the summer. On Monday, the pharma company announced a $1.4 billion acquisition of ...